Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists’ practice

Background Central to the design of a randomised controlled trial (RCT) is a calculation of the number of participants needed. This is typically achieved by specifying a target difference, which enables the trial to identify a difference of a particular magnitude should one exist. Seven methods have been proposed for formally determining what the target difference should be. However, in practice, it may be driven by convenience or some other informal basis. It is unclear how aware the trialist community is of these formal methods or whether they are used. Purpose To determine current practice regarding the specification of the target difference by surveying trialists. Methods Two surveys were conducted: (1) Members of the Society for Clinical Trials (SCT): participants were invited to complete an online survey through the society’s email distribution list. Respondents were asked about their awareness, use of, and willingness to recommend methods; (2) Leading UK- and Ireland-based trialists: the survey was sent to UK Clinical Research Collaboration registered Clinical Trials Units, Medical Research Council UK Hubs for Trial Methodology Research, and the Research Design Services of the National Institute for Health Research. This survey also included questions about the most recent trial developed by the respondent’s group. Results Survey 1: Of the 1182 members on the SCT membership email distribution list, 180 responses were received (15%). Awareness of methods ranged from 69 (38%) for health economic methods to 162 (90%) for pilot study. Willingness to recommend among those who had used a particular method ranged from 56% for the opinion-seeking method to 89% for the review of evidence-base method. Survey 2: Of the 61 surveys sent out, 34 (56%) responses were received. Awareness of methods ranged from 33 (97%) for the review of evidence-base and pilot methods to 14 (41%) for the distribution method. The highest level of willingness to recommend among users was for the anchor method (87%). Based upon the most recent trial, the target difference was usually one viewed as important by a stakeholder group, mostly also viewed as a realistic difference given the interventions under evaluation, and sometimes one that led to an achievable sample size. Limitations The response rates achieved were relatively low despite the surveys being short, well presented, and having utilised reminders. Conclusion Substantial variations in practice exist with awareness, use, and willingness to recommend methods varying substantially. The findings support the view that sample size calculation is a more complex process than would appear to be the case from trial reports and protocols. Guidance on approaches for sample size estimation may increase both awareness and use of appropriate formal methods.

[1]  Philippe Ravaud,et al.  Reporting of sample size calculation in randomised controlled trials: review , 2009, BMJ : British Medical Journal.

[2]  Martin P Eccles,et al.  Response rates in postal surveys of healthcare professionals between 1996 and 2005: An observational study , 2009, BMC health services research.

[3]  D. DeMets,et al.  Fundamentals of Clinical Trials , 1982 .

[4]  References , 1971 .

[5]  T. Perneger,et al.  What differences are detected by superiority trials or ruled out by noninferiority trials? A cross-sectional study on a random sample of two-hundred two-arms parallel group randomized clinical trials , 2010, BMC medical research methodology.

[6]  Alexander J Sutton,et al.  Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. , 2010, Journal of clinical epidemiology.

[7]  P. Fayers,et al.  Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. , 2014, Health technology assessment.

[8]  Nicola J Cooper,et al.  Evidence synthesis as the key to more coherent and efficient research , 2009, BMC medical research methodology.

[9]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[10]  M. A. Best Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[11]  Steven A. Julious,et al.  Sample Sizes for Clinical Trials , 2009 .